Moderna outlines 2027 cash costs of about $4 billion
At analyst day, Moderna said it expects approximately $9 billion in year-end 2026 liquidity and around $4 billion in cash costs in 2027, with annual costs of $4 billion–$4.5 billion through 2030, largely driven by oncology investment. It is preparing manufacturing and commercialization capabilities for intismeran with Merck, pending regulatory approval, and expects gross-margin expansion of about 10 percentage points. Shares fell as investors weighed the spending against limited visibility beyond 2026.
Moderna and Merck report a 42% reduction in melanoma recurrence or death risk
In a Phase III melanoma trial, intismeran plus Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone. Moderna and Merck are preparing a regulatory submission, with a potential approval and launch discussed for 2027. The reports also describe uncertainty around approval, manufacturing capacity, costs, patient turnaround times and commercial returns; the therapy remains unapproved.
Commentators weigh Moderna’s rally against valuation and execution risks
The articles discuss Moderna’s sharp share-price gains, high valuation and reliance on newer products and pipeline candidates. They cite risks from COVID vaccine dependence, clinical and regulatory uncertainty, cash burn, debt and dilution, while noting progress in respiratory vaccines and oncology. One valuation analysis said the shares remained overvalued relative to its model, and another noted bearish options positioning ahead of the quarterly report.
MSCI announced that Moderna will be added to the MSCI World Index as part of its November 2026 index review, effective at the close of November 30. The review also includes changes to other MSCI global, small-cap, all-cap and frontier-market indexes. The inclusion could increase Moderna’s visibility among benchmark-tracking funds.
Moderna reports $1.31 billion in third-quarter revenue and raises its 2026 outlook
Moderna reported third-quarter revenue of $1.31 billion, up 29% year over year, and net income of $162 million, returning to quarterly profitability. It raised its 2026 revenue-growth outlook to 15%–25%, reduced expected R&D spending and increased its year-end cash forecast to $8.1 billion–$8.3 billion. International COVID-19 vaccine sales contributed to growth, and the company reported positive Phase 3 melanoma results and U.S. approval of its seasonal flu vaccine.
Moderna study finds lower COVID-19 risks with mNEXSPIKE than Comirnaty
A JAMA Network Open study of 294,499 U.S. veterans aged 65 and older found mNEXSPIKE was associated with 35.9% lower risk of medically attended COVID-19 and 47% lower risk of COVID-19 hospitalization than Comirnaty. An exploratory analysis found lower risk of hospitalization involving a major adverse cardiovascular event. The observational study was supported by Moderna and had limitations, including possible residual confounding and limited generalizability.
Piper Sandler raises Moderna’s price target to $305
Moderna shares rose after Piper Sandler raised its price target to $305 from $230 following a quarterly revenue beat and an improved 2026 outlook. Piper’s positive view depended heavily on Moderna’s melanoma vaccine with Merck, for which potential approval was expected in 2027. Goldman Sachs raised its target to $195 but maintained a Neutral rating, citing valuation concerns; investors were also watching upcoming kidney cancer data.
Analysts raise Moderna fair-value estimate to $145.42
Analysts raised Moderna’s fair-value estimate from $135.84 to $145.42 per share, citing Q3 execution and promising intismeran melanoma data. Several firms also lifted price targets, while some remained cautious about valuation and clinical risks as the company expands into additional cancers. The updated assumptions included higher revenue growth but lower net margins, a higher future P/E and a slightly higher discount rate.
Canada authorizes Moderna’s flu and flu-COVID vaccines
Health Canada authorized Moderna’s mFLUSIVA seasonal influenza vaccine and mCOFLU influenza-COVID-19 combination vaccine for adults aged 50 and older, making Canada the first country to approve both. The approvals were supported by Phase 3 trials. Moderna said it would work with Canadian authorities and immunization partners on future availability, while both products remained under review in other markets.
WHO advisers recommend Moderna’s Ebola vaccine for a Phase 2/3 study
WHO’s Technical Advisory Group recommended Moderna’s investigational mRNA-1469 vaccine for a Phase 2/3 efficacy study in the Democratic Republic of the Congo, subject to regulatory approval. The recommendation followed encouraging preclinical results and Phase 1 data showing the vaccine was generally well tolerated and produced robust antibody responses after one dose. CEPI committed up to $58.5 million toward development and trial-dose manufacturing.
Moderna reports four responses in an early multiple myeloma trial
In initial Phase 1/2 results for mRNA-2808, an investigational therapy encoding T-cell engagers targeting BCMA, GPRC5D and FcRH5, four of 11 evaluable, heavily pretreated patients had confirmed responses. All three engagers were detected in plasma, and no dose-limiting toxicities or treatment-related serious adverse events occurred. However, 41.7% of patients experienced Grade 3 or higher treatment-related events, predominantly hematologic.
Moderna raises $2.6 billion through convertible notes
Moderna expected cash and investments to decline to $4.7 billion–$5.2 billion by year-end, though it subsequently raised $2.6 billion through convertible notes. The article also lists potential catalysts including third-quarter COVID vaccine sales, possible 2026 analysis of Intismeran kidney cancer data and year-end cash results expected in February 2027. COVID vaccine sales remained central to revenue.